Edwards Lifesciences Corp banner

Intrinsic Value

The intrinsic value of Edwards Lifesciences Corp (EWL) under the Base Case is 72.94 EUR per share. Compared with the current market price of 92.74 EUR, the stock appears Overvalued by 21% .

The intrinsic value is calculated using the DCF method.

Do our valuations actually work? See backtest results .

EWL Intrinsic Value
€72.94
Overvaluation 21%
Intrinsic Value
Price €92.74

EWL is valued in line with its history. A premium of this size has been typical over the past 5 years.

Alert me when EWL is below its intrinsic value
Today €58.35 · 37.1% below the current price
Alternatives to EWL

Fundamental Analysis

What Edwards Lifesciences Does

Health Care

Edwards Lifesciences makes medical devices for people with serious heart disease. Its main products are replacement heart valves, including minimally invasive valves that can be delivered through a catheter instead of open-heart surgery, plus monitoring tools used in intensive care and during surgery. The company focuses on conditions where the heart cannot pump or valve properly, so its products help doctors treat patients with structural heart disease and monitor them closely in the hospital.

Headquarters
United States of America US
Employees
16 000
IPO date
Mar 27, 2000
Read the full company overview
View Company Overview

Edwards Lifesciences has a narrow economic moat

No Moat Narrow Wide

Protected valve technology, demanding approval requirements and the time doctors spend learning Edwards’ devices make it difficult for rivals to win business on price alone. These barriers provide lasting protection, although established competitors such as Medtronic and Abbott offer alternatives.

Read the full moat analysis
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Latest Earnings Call

Q3 2026 · November 4, 2026

Broad-based third-quarter strength led Edwards to raise its full-year outlook, while management emphasized widening TAVR access and developing new treatment opportunities.

What management delivered: 2 better than forecast

Open the earnings call
EPS
$0.80
Expected
$0.73
Surprise
+9.6%
Stock, next trading day
+1.5%
View Earnings Call

Edwards Lifesciences insiders are selling within their usual range

Insider trading · Last trade on Oct 8, 2026

Sold $14.4m 9 insiders
Bought $0 Nobody bought
Trades by date
Open insider trading

Past 12 months

Continue EWL Research

Decided on Edwards Lifesciences? Get an email when EWL reaches the price you’d buy at. Free with an account.

Other Edwards Lifesciences listings

What is the Intrinsic Value of one EWL stock?

The intrinsic value for Edwards Lifesciences Corp (EWL) under the Base Case is 72.94 EUR.

Is EWL stock undervalued or overvalued?

Compared with the current market price of 92.74 EUR, the stock appears Overvalued by 21% .

How reliable are our estimates? See how past valuations played out
Back to Top